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their trust on quality (better medical cares, drugs and equipments), and also doctors
may use cost-saving strategies such as continuous prescriptions to help them. CON-
CLUSIONS: The attributes for GERD outpatients’ choices of accessing medical facili-
ties have been identiﬁ ed. Participants with different socioeconomic backgrounds in 
Southern Taiwan are aware of the increasing OPP, but the current OPP does not seem 
to impact on the affordability and accessibility of treatment. Future study is going to 
determine the relative importance of attributes and how different OPP can inﬂ uence
on decision making.
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PATIENTS USING ELECTRONIC MEDICAL RECORDS (EMR)
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OBJECTIVES: To examine PPI utilization among patients with non-erosive GERD
(NERD), erosive esophagitis (EE) and Barrett’s esophagus (BE). METHODS: We
conducted an observational cohort study using EMRs obtained from a fully integrated 
health delivery system located in the mid-Atlantic region of the US. Incident cases of 
BE, EE, and NERD were identiﬁ ed between July 1, 2004–January 25, 2007. Patients 
were required to have encounter data for 6 months before and 12 months following 
their index diagnosis. Frequency of PPI use, time to PPI initiation, dosing frequency,
and switching patterns among the three cohorts at 52 weeks post diagnosis were
compared using NERD as the reference group. RESULTS: 12,273 patients met the 
inclusion criteria and included 79.6% NERD, 17.9% EE and 2.3% BE patients. A 
higher proportion of NERD and EE patients received a PPI as their initial pharmaco-
logic therapy (90.5% and 92.2%; p  0.0140) compared to 70.5% (p  0.0001) of 
BE patients. Greater than 90% of NERD and EE (p  0.0001) patients started initial
PPI therapy within 8 weeks post diagnosis compared to 71.6% (p  0.0001) of BE
patients. Majority of patients were prescribed once daily PPI therapy [NERD 79.4%;
BE 68.2% (p  0.0001); EE 73.6% (p  0.0001)] with a substantial proportion of 
patients on twice daily therapy [NERD 12.3%; BE 31.3% (p  0.0001); EE 15.2% 
(p  0.0003)]. Switching among initial PPI therapy occurred more often within BE 
patients (14.4%; p  0.0083) as compared to NERD and EE patients (9.0%, 9.3%; 
p  0.6896). There were no signiﬁ cant differences in patients reducing their PPI fre-
quency from twice daily to once daily therapy (NERD 24.5%, BE 18.5%, EE 25.7%).
CONCLUSIONS: A substantial proportion of patients with GERD are on twice daily 
PPI regimen. Switching between various PPI agents is common among GERD patients.
Future research should focus on the clinical and economic implications of twice daily 
PPI use and switching among PPIs.
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OBJECTIVES: To retrospectively examine patterns of PPI treatment in commercially
insured adults (q18 years of age) with selected upper gastrointestinal conditions.
METHODS: Patients were selected if they were newly dispensed a PPI in 2003 or
2004 (ﬁ rst PPI claim is “index date”) and were continuously enrolled in the 12 months
pre- and post-index. Based on ICD-9 CM diagnosis codes, four disease cohorts were
constructed: GERD, GERD-like symptoms (787.1), Erosive Esophagitis (EE), and
Barrett’s Esophagus (BE). Post-index length of treatment (LOT) was estimated as the 
cumulative days of index PPI therapy dispensed. Patients were considered “adherent” 
if the medication possession ratio (LOT/365 days) was q80%. Discontinuation of PPI 
medication was deﬁ ned as 90 days without available treatment. PPI adherence, dis-
continuation and LOT were compared between the four subgroups. RESULTS: The 
study population included 138,598 patients (91.7% GERD; 1.6% GERD-like symp-
toms; 4.1% EE; 2.7% BE). Mean (SD) number of reﬁ lls of index PPI for patients with
GERD-like symptoms, GERD, EE and BE were 2.9 (3.3), 3.2 (3.4), 4.1 (3.6) and 4.2 
(3.6), respectively (p  0.01). LOT was signiﬁ cantly (p  0.01) longer for BE [197.4
days (120.9)], EE [194.9 (121.4)], and GERD patients [154.3 (116.6)] compared to 
patients with GERD-like symptoms [142.9 (115.8)]. There were signiﬁ cant differences 
(p  0.01) in adherence to index PPI between BE patients (33.2%), EE patients 
(32.7%), GERD patients (20.7%), and patients with GERD-like symptoms (18.8%).
During the study period, a higher proportion of patients with GERD-like symptoms
(63.6%, p  0.01), GERD (58.2%, p  0.01) and EE (40.3%, p  0.04) discontinued
PPI treatment compared with BE patients (37.9%). CONCLUSIONS: Patients with 
BE and EE, generally considered as a more severe form of GERD, showed higher 
adherence with and lower discontinuation of PPI treatment compared to patients with 
GERD and GERD-like symptoms. Additional studies of the clinical and economic
implications of discontinuing PPI treatment should be conducted.
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OBJECTIVES: Medical errors are a major problem in the United States. The Institute
of Medicine estimates that medical errors cost the U.S. approximately $37.6 billion, 
of which $17 billion are preventable. Our objectives are to develop a Bayesian network 
(BN) model to detect value errors in blood lab and to compare performance of our 
model with an existing automated ruled-based approach (LabRespond), and a logistic 
regression model. METHODS: The sample consisted of 5800 observations from the 
National Health and Nutrition Examination Survey dataset. The performance was 
assessed by the area under the receiver-operating characteristics curves (AUCs) using 
a 10-fold cross validation methodology. Small, medium, and large errors were ran-
domly generated and added to liver enzymes (AST, ALT, and LDH). The outcome of 
interest was the correct detection of liver enzymes as “error” or “normal.” In BN, the
outcome was predicted by exploiting probabilistic relationships among AST, ALT, 
LDH, and gender. Addition to AST, ALT, LDH, and gender, LabRespond required 
more analyte information (GGT, ALP, and total bilirubin) to achieve optimal predic-
tion. For the Logistic model, the model was determined by stepwise selection among 
analytes that were signiﬁ cant at A  0.05. RESULTS: The BN was predictive of added 
errors with small [AUC  0.644 (0.023)], medium [AUC  0.787 (0.019)], and large 
[AUC  0.903 (0.013)] error sizes; and performed signiﬁ cantly better than LabRe-
spond [z  1.99 (p  0.05), z  2.77 (p  0.01), and z  4.57 (p  0.001), respectively]
and the logistic model [z  1.71 (p  0.05), z  5.28 (p  0.001), and z  8.87 (p 
0.001), respectively]. CONCLUSIONS: A BN model detects errors better and with 
less information than existing automated models, suggesting that Bayesian model can 
be an effective means for reducing medical costs in the laboratory
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OBJECTIVES: Retrospective chart review data can be important inputs to economic 
models or other burden of illness evaluations. Traditional paper-based approaches and 
local site monitoring can be cost and time prohibitive. A case study of an efﬁ cient,
adaptable design and electronic data capture methodology for the collection of multi-
national clinical, and resource utilization chart data is presented. METHODS: A ret-
rospective chart review study of patients with CLD, bridging ﬁ brosis, and cirrhosis 
from 10 liver centers (7 US; 3 EU) was conducted (eligibility period  6/1/04 to 
5/31/06; study period  minimum of 12 months). Demographics, clinical and health
economic data were collected. All potentially eligible patients were identiﬁ ed by the
sites, but the ﬁ nal random selection of the target cohort and its disposition was con-
trolled centrally through a web-based tool. RESULTS: Data from 864 patient charts 
(62.8% male; mean age 52.3 years) were abstracted over one year. Data abstraction
spanned 22 to 52 weeks depending on the site and its resources. The standardized
eCRF worked well for the capture of multi-national data. Quality was maintained by
electronic validation rules applied at the point of data entry and shown by data com-
pleteness and a minimum of data queries. Database lock was achieved in less than
three weeks following the last data entry. Remote training of data abstractors by
WebEx proved efﬁ cient. Data have been used successfully to inform clinical trial design
and to estimate the cost of illness. Main challenges included timely contracting of sites,
the need for site-speciﬁ c algorithms to identify charts, and analytical methods tailored
to naturalistic data. CONCLUSIONS: A well designed CRF and web-based cohort
control and data capture tool can provide a practical and efﬁ cient means of collecting 
high quality, multi-national outcomes data without the need for costly site visits and 
local monitoring.
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OBJECTIVES: Since it houses the digestive system, the least sign of digestive problems
shows up in the stomach. Fermentation, carbonated drinks, air swallowed while 
eating, constipation  .  .  .  but also stress or strong emotions: it becomes painful and
bloated. Evaluate the beneﬁ t of using “afﬁ nex ﬂ at stomach” as part of a weight loss 
regime. METHODS: Prospective pragmatic evaluation under real-life conditions. The
pharmacist gave a double questionnaire along with the product to all adult female
customers who had started (or were about to start) a weight loss regimen and who
asked the pharmacy for help or advice. TOOLS Validated questionnaires were used 
(SF 12 and BISS (Body Index States Scale)). Moreover, waist measurement and symp-
toms were assessed and organized in a single score (Pain, Bloating, Belching, Spasm, 
Transit problems, Flatulence and Nausea). RESULTS: A total of 178 female subjects
included, age: 40.8 o 12.3 years with an average BMI of 23.5 o 3.8 kg/m², the score 
of the symptoms was 146. With regards to QoL scales, the average scores on inclusion 
A62 Abstracts
for the SF-12 were 52.7 for the physical dimension (PD) and 40.7 for the mental 
dimension (MD). The average score obtained on the BISS scale is 22.64 and a ques-
tionnaire to assess the perceived stress indicates a stress level of 19.01. At 14 days,
the decrease in waistline was 1.66 cm (p  0.001) and the symptoms score was 91 
(p  0.05). With regards to the scales dealing with QoL, average scores at D14 for
SF-12 were 53 for PD and 43.4 for MD. Improvement of the mental dimension (p 
0.02). Average score obtained on the BISS scale is 26.34 (p  0.01) Perceived stress
level was 17.9 (p  0.003). CONCLUSIONS: At the end of the 14 days, the reduction
in waist circumference is statistically signiﬁ cant. We also noted an improvement in the 
overall symptoms score; an improvement that has been conﬁ rmed by an improvement 
of all symptoms.
HEALTH CARE INTERVENTIONS – Clinical Outcomes Studies
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OBJECTIVES: Treatment with LIPUS results in greater increases in bone density and 
greater reductions in bone gap area as compared to sham control in tibia fractures 
with NU(no progression of healing for at least four months). Fractures that do not 
heal after several months represent signiﬁ cant clinical and economic burden to health
care systems. Five to ten percent of all fractures are eventually classiﬁ ed as
nonunions[NU], fractures that fail to heal or will not heal without intervention.
Interventions include treatment by cast/brace, surgery, electrical stimulation, or low-
intensity pulsed ultrasound[LIPUS]. METHODS: Two primary effectiveness variables, 
change of bone density and gap area during treatment, were selected as surrogates for
bone healing. Abbreviated treatment period was maximum that sham treatment could 
be administered ethically. Both variables measured by blinded central reviewers from
CT-scans taken before/after termination of treatment. All adverse events recorded,
evaluated. Treatment duration was 16 weeks. Patients instructed to apply device once
daily for 20 minutes. Control (sham) devices were visually identical but did not
transmit ultrasound waves. Neither patients nor physicians could recognize shams.
RESULTS: A total of 101 patients enrolled (51 LIPUS, 50 sham), mean age 42.6 
(active) versus 45.1 years (sham). Based on log-transformed data, mean improvement 
in bone density was 1.34 (90% CI 1.14 to 1.57) times greater for patients randomized
to LIPUS compared to sham (p  0.002). A mean reduction in bone gap area also 
favored LIPUS treatment (p  0.014). CONCLUSIONS: Double-blind, intent-to-treat 
analyses demonstrated statistically signiﬁ cant superior effectiveness for LIPUS device 
compared to sham in terms of both endpoints over 16 weeks of treatment. Estimated
increase in bone density among patients randomized to LIPUS treatment was 34% 
greater than among patients randomized to sham. A signiﬁ cantly greater mean reduc-
tion in bone gap area after LIPUS treatment was also shown. Evaluation of adverse 
events showed that ultrasound therapy is safe.
HEALTH CARE INTERVENTIONS – Cost Studies
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SOCIOECONOMIC STATUS AND COST OF CARE IN THE ELDERLY
UNDERGOING MAJOR ORTHOPEDIC SURGERY
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OBJECTIVES: Socioeconomic status is associated with patients’ health behaviors,
health problems as well as the quality of care they receive. We examined data on U.
S. elderly patients undergoing major orthopedic surgery to determine whether socio-
economic status was associated with cost of care for patients with similar access to 
health care provided by Medicare. METHODS: We used the 2004–2006 Medicare 
data to identify all patients undergoing major orthopedic surgery. We used previously 
constructed and validated SESScore ™, which is a summary measure of socioeconomic 
status for each U.S. zip code, using data from the 2000 U.S. Census. We assessed the
effect of SESScore ™ on cost of care while controlling for other patient characteristics, 
and then examined the extent to which disparities in cost of care could be attributed 
to differences in hospital factors. Fixed effect models were used. RESULTS: SESScore 
™ was a signiﬁ cant predictor of cost of care for major orthopedic surgery. Comparing 
the lowest quintile of SESScore ™ to the highest, the cost difference was positive and 
signiﬁ cant (p  0.000). After further adjustment for hospital factors, the difference
was reduced. Within hospitals, there were only small differences in adjusted cost of 
care by patients’ socioeconomic status. CONCLUSIONS: When undergoing major 
orthopedic surgery, patients with a lower socioeconomic status have higher rates of 
cost of care than patients with a higher socioeconomic status, despite similar insurance 
coverage provided by Medicare.
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OBJECTIVES: Myxomatous mitral valve disease (MMVD) presents a frequent heart 
problem in dogs. The inodilator pimobendan has shown to increase survival time of 
affected dogs when compared to the ACE inhibitor benazepril. The objective of this 
study was to estimate the cost-effectiveness of pimobendan compared to generic
benazepril for treatment of MMVD in dogs in Germany. METHODS: A Markov 
model was developed to calculate costs and beneﬁ ts of pimobendan and benazepril
over a 1-year time horizon in dogs with MMVD on concurrent furosemide treatment. 
The model structure allowed for a differentiation in costs and transition probabilities
between treatment start and maintenance treatment, and included the health states 
asymptomatic MMVD, symptomatic MMVD, treatment failure, euthanasia, and
sudden death. Most transition probabilities were based on randomized controlled
trials. Input-data on treatment pattern were derived from published literature, and
cost data taken from ofﬁ cial price and tariff lists (year 2008, perspective of the dog 
owner). Missing data were obtained from experts in canine cardiology. RESULTS:
Over the 1-year time horizon, mean total therapy cost per dog on pimobendan was 
€463.55 versus € 284.29 for benazepril. Mean survival was 274 days and 129 days
for dogs on pimobendan and benazepril, respectively; resulting in a cost of € 1.24 for 
each additional day of life on pimobendan. Mean costs per treatment day were lower 
with pimobendan (€ 1.69) when compared to benazepril (€ 2.20). Extensive one-way
and probabilistic sensitivity analyses conﬁ rmed the robustness of the results. CON-
CLUSIONS: Pimobendan is a cost-effective treatment of MMVD if the dog owner is
willing to pay a price below the normal range of food costs in Germany for each 
additional day of life. Lower total treatment costs for benazepril are merely attributed 
to a shorter survival, as pimobendan resulted in less costs per treatment day compared
to benazepril.
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OBJECTIVES: Myxomatous mitral valve disease (MMVD) presents a frequent heart 
problem in dogs. The objective of this study was to estimate the cost-effectiveness of 
pimobendan compared to benazepril for treatment of MMVD in dogs in Switzerland.
METHODS: A Markov model including the health states asymptomatic MMVD, 
symptomatic MMVD, treatment failure, euthanasia, and sudden death, was adapted 
to Switzerland. Costs (year 2008, perspective of the dog owner) and beneﬁ ts (life days 
gained, time without symptoms of heart failure) were calculated over a 1-year time
horizon for dogs on pimobendan or benazepril respectively, both on concurrent furo-
semide treatment. Most transition probabilities were based on randomized controlled 
trials. Missing data and input-data on treatment pattern were obtained from experts 
in canine cardiology. RESULTS: Mean survival over the 1-year time horizon was 274 
days for dogs on pimobendan versus 129 days for dogs on benazepril. Time spent
without any symptoms of heart failure was 86 days for pimobendan versus 15 days
for benazepril. Mean total therapy cost per dog on pimobendan was CHF 905.68
versus CHF 546.52 for benazepril; resulting in a cost of CHF 2.48 for each additional
day of life on pimobendan. Mean costs per treatment day were lower with pimoben-
dan (CHF 3.31) compared to benazepril (CHF 4.24). Extensive one-way and proba-
bilistic sensitivity analyses conﬁ rmed the robustness of the results. CONCLUSIONS:
Pimobendan is a cost-effective treatment of MMVD if the dog owner is willing to pay
a price within the normal range of food costs for each additional day of life. The 
results indicate a better quality of life of dogs on pimobendan, as they spent substan-
tially more time without any symptoms of heart failure compared to dogs on benaz-
epril. Lower total treatment costs for benazepril are merely attributed to a shorter 
survival, as pimobendan resulted in less costs per treatment day.
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OBJECTIVES: Hemostatic agents (HAs) are efﬁ cacious in reducing blood loss during
surgery, which may impact post-operative health care utilization and length of stay 
(LOS). The purpose of this study was to compare expected and actual LOS by choice
of HA in cardiac procedures. METHODS: Hospital data were extracted from a large 
U.S. hospital-based, service-level comparative database. Procedures conducted between 
2003 and 2006 were identiﬁ ed using principal ICD-9 codes and limited by Diagnostic
Related Groups (DRGs). Four cohorts for comparison were Floseal, Surgicelthrombin, 
Gelfoamthrombin, and other. Expected LOS was derived using 2006 Centers for
Medicare and Medicaid (CMS) geometric mean LOS by DRG and two-part regression
models were created to assess outcome. RESULTS: A total of 36,950 discharges were 
included. Floseal use was associated with signiﬁ cantly less likelihood of exceeding the 
